EV Ownership in 2025 Comes With Higher Costs for Insurance, Depreciation, and Charging
EV makers trumpet an average transaction price of $59,255 in April 2025, yet that "deal" hides an 11.6 percent incentive discount before you even charge the battery. Add the $1,500 for home-charger installation, and you're already $10,000 beyond a comparable gas SUV, incentives aside.
EV proponents love to tout "fuel savings," but grid electricity now averages 16.13 ¢/kWh across the U.S. At 30 kWh per 100 miles, that's $4.84 in juice, or about a third of gasoline's $14 for 100 miles at $3.50/gal and 25 mpg. Nice, right? Yet the devil lurks in the details: public fast-charging premiums, demand surcharges and urban "idle" fees can double that rate in a heartbeat. Maintenance feels breezy at $0.04/mile versus $0.08/mile for an ICE (saving roughly $3,000 over five years), but cheap brake pads can't cover body-shop bills when a battery swap runs $12,000 out of warranty.
An early-adopter premium evaporates faster than electrons at the charging station. When it comes to depreciation, EVs lose an average 58.8 percent of their value over five years, versus 45.6 percent for gas cars. On a $60,000 EV, that's a $35,300 hit; a similar ICE drops "only" $27,300.
Expect to shell out about 20 percent more in insurance. On average, you're looking at $337 monthly for EVs versus $281 for gas cars, thanks to pricier parts and repair times. That's roughly $3,000 extra over five years.
• Upfront Premium: $6,879 in incentives subtracted from MSRP doesn't offset the $10,000 charger & dealer markup.• Depreciation Gap: EV owners bleed an extra $8,000 in resale losses over five years.• Insurance Levies: EVs tack on $3,000 more in premiums.• Infrastructure Fees: City curb-side charging, demand surcharges, and road-usage taxes lurk in 2025's policy playbook.
Your next EV purchase should come with a spreadsheet, not just an excited thumb-twitch to "order now." Demand transparent TCO projections from dealers. Insist on five-year cost estimates that include charger installation, insurance, depreciation, and all the "voltage-supply chain" fees they'd rather bury in small print. If automakers want EW (electrification wow) to catch on, they need to own these costs as boldly as they tout eco-credentials. Otherwise, consumers will unplug from sticker hype and power down to real-world numbers.
Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Innovative company's futuristic camper van could change the way we vacation: 'Just a more efficient way of traveling'
Camping is already one of the most sustainable ways to go on vacation, but designers in the Netherlands have taken things a step further. BBC travel reporter Rob Bell had the opportunity to tour the world's first solar-powered campervan, Stella Vita, created by Solar Team Eindhoven. This campervan is completely powered by solar and able to recharge without the need to plug into EV charging stations, making road trips and adventures truly limitless. Conceptualized in 2020, Stella Vita is a self-sustaining house on wheels, featuring a shower, a toilet, a cooking area, a sleeping area, and a raisable solar roof with extended panels for additional solar surface. "The vehicle generates enough solar energy to drive, shower, watch TV, charge your laptop, and make coffee," the company wrote in a Facebook post about the innovative campervan. As long as it's a nice, sunny day, the car will recharge while you drive or stop to grab coffee or lunch, ensuring you always have enough range to get to where you're going. This constant charging helps overcome the fear that some have that their EV will run out of range on long-distance travel, also known as range anxiety. "So how many kilometers can it go, maximum?" Bell asked. "Roughly, on a sunny day in the Netherlands, it's around 750 kilometers (466 miles)," Bob from the Stella Vita team answered. This is an impressive range, even surpassing that of new electric vans. An electric vehicle's maximum range is determined, in part, by a vehicle's battery health. As an electric vehicle (EV) endures regular wear and tear, the battery loses efficiency, and performance can suffer. If you were to install home solar panels, which of these factors would be your primary motivation? Energy independence Lower power bills Helping the planet No chance I ever go solar Click your choice to see results and speak your mind. Monitoring your battery health can give you a good idea about your vehicle's maximum range, as well as your used EV's projected value. Data on the used EV market found that used EV sales increased 63% from 2023 to 2024, highlighting the consumer desire to find affordable ways to join the clean energy movement. A used EV is not only better for the environment than conventional gas-powered cars due to zero tailpipe pollution, but EVs also provide car owners with savings on routine maintenance and fuel costs. Due to fewer moving parts and an electric engine, EVs do not require traditional oil or other fluid changes, and they do not require fueling up — just recharging. Although they are still mostly conceptual, solar EVs, like the Stella Vita solar campervan, do not need constant plug-ins for recharging, which would make owning an EV even better. But EV owners can still take advantage of the benefits that solar offers. Charging your EV at home with solar is cheaper than using public charging stations or relying on the electric grid. With government incentives available for solar panels, you could enjoy even more savings with EV ownership and installing solar at your home. EnergySage offers a free tool to help homeowners compare quotes from vetted local solar installers, which can save homeowners up to $10,000 on new projects. Solar EVs, like Stella Vita, could change the future of transportation and traveling. "This is even more self-sustainable, even more self-reliant, and just a more efficient way of traveling," the Stella Vita team said. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Associated Press
21 minutes ago
- Associated Press
SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development
CHINO HILLS, CA / ACCESS Newswire / June 4, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, health and wellness solutions, proudly announces the appointment of Dr. Lucia Piccotti, PhD, EMBA, as a key member of our team. Dr. Piccotti will serve on the advisory board, advising on the development of cutting-edge cosmeceuticals and personal health products utilizing SOHM's cutting-edge technological advancements. Dr. Piccotti is a distinguished biomedical scientist and strategic business leader, bringing over a decade of expertise in blending scientific research with entrepreneurial innovation. Her career has taken her through pivotal roles in both Fortune 500 companies and dynamic biotech startups, where she has excelled in translating complex biomedical concepts into impactful consumer products and business strategies. Most recently, Dr. Piccotti served as Senior Director of Strategic Innovation at Kiromic Biopharma, a biotechnology company at the forefront of cell therapies for cancer. Her contributions were instrumental in navigating the company's growth through the critical phases of pre-IPO and post-IPO operations. Notably, she led innovative initiatives that utilized exosome technologies for skin health, showcasing her extensive knowledge and versatility in both therapeutic and consumer health applications. In addition to her role at Kiromic, Dr. Piccotti is the founder of Iguvia LLC, a consulting firm that specializes in cosmeceuticals and health products. Since 2018, she has directed multiple projects focused on phytoextract-based topical applications, drawing on her in-depth expertise in skin health and bioactive formulation. Earlier in her career, Dr. Piccotti was a Lead Scientist at Kimberly-Clark Corporation, where she advanced biomedical research and product development in the personal care and cosmeceutical sectors. Her innovative work has resulted in numerous patents and industry-recognized advancements, particularly in the use of phytoextracts and topical formulations. Dr. Piccotti's impressive track record includes managing cross-functional teams and complex research studies, as well as collaborating with various departments, including Marketing and Regulatory Affairs. Her extensive network within the medical community, including connections with top institutions like the University of Texas and MD Anderson Cancer Center, positions her uniquely to drive SOHM Inc.'s growth and innovation in the industry. 'With Dr. Piccotti on board, we are poised to elevate our approach to cosmeceuticals and personal health products,' said David Aguilar, COO of SOHM Inc. 'Her strategic thinking and innovative mindset will significantly enhance our capabilities and ensure we continue to deliver high-quality solutions that meet the evolving needs of consumers.' Dr. Piccotti graduated with a PhD in Biochemistry, where her thesis focused on liposomal delivery of anionic phospholipids to support mitochondrial bioenergetics, with implications for cellular aging. She also holds an MS in Chemistry with a thesis in Synthetic Organic Chemistry, and an Executive MBA, demonstrating her commitment to both scientific excellence and business leadership. Her collaborative leadership style and entrepreneurial spirit will be invaluable as she helps SOHM navigate the complexities of the cosmeceutical market. About SOHM, Inc.: SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery. For further information regarding this announcement or to explore potential collaborations, please contact: SOHM, Inc.: Name: Baron Night, CEO/Dr. David Aguilar, COO Email: [email protected] Phone: (714) 522-6700 Safe Harbor Statement: This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on SOURCE: SOHM, Inc press release
Business Wire
an hour ago
- Business Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston. Cadrenal executives will participate in one-on-one meetings with investors and potential partners to provide key updates on the Company's strategic direction and clinical development of its lead asset, tecarfarin. Those interested in meeting with Cadrenal management should request a meeting through the Conference meeting portal or contact Investor Relations at cadrenal@ The BIO International Convention is the world's largest and most comprehensive biotechnology event, convening over 20,000 industry leaders from across the global life sciences ecosystem. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options. Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn.
